Researchers are studying the therapy as part of a national effort to keep COVID-19 patients out of the hospital
UT Southwestern is one of several universities and companies across the country participating in the trial. “The health care system is overwhelmed, and I think that if we can find something that can be administered as an outpatient and keep people out of the hospital, that’s important,” she said. Preliminary data out of South Africa show omicron appears to cause less severe disease than previous versions of COVID-19, but that it seems to be more easily transmitted. The strain is now the dominant variant in the U.S., just over a month after it was first identified in South Africa., with coronavirus patients making up nearly 17% of hospital bed capacity in the North Texas trauma service area on Monday, according to data from the Dallas-Fort Worth Hospital Council.
Scientists are racing for new treatment options, a fact that was taken into consideration in the ACTIV-2 trial’s design. Its randomized and adaptive platform of phase 2 and phase 3 studies allows promising therapies to be added or removed over the course of the trial to test a variety of new agents.
Thank you for letting folks know about SAB-185. Think we have to use the same science that our bodies already use to effectively fight disease. SABBantibody gives us this! EddieSu24820728
Because there has to be better than one.